Axsome Therapeutics, Inc. (FRA:19X)

Market Cap	6.59B
Revenue (ttm)	478.36M
Net Income (ttm)	-195.63M
Shares Out	n/a
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120
Average Volume	32
Open	129.20
Previous Close	128.05
Day's Range	129.20 - 129.20
52-Week Range	70.00 - 135.55
Beta	n/a
RSI	61.67
Earnings Date	Feb 13, 2026

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 683
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 19X

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD